The crucial roles of m6A RNA modifications in cutaneous cancers: Implications in pathogenesis, metastasis, drug resistance, and targeted therapies

被引:5
作者
Huang, Cong [1 ]
Zhang, Kaoyuan [2 ]
Guo, Yang [1 ]
Shen, Changbing [2 ]
Liu, Xiaoming [2 ]
Huang, Haiyan [2 ]
Dou, Xia [2 ]
Yu, Bo [1 ]
机构
[1] Hong Kong Univ Sci & Technol, Peking Univ Shenzhen Hosp, Shenzhen Peking Univ, Dept Dermatol,Skin Res Inst,Med Ctr, Shenzhen 518036, Guangdong, Peoples R China
[2] Peking Univ Shenzhen Hosp, Skin Res Inst, Dept Dermatol, Shenzhen 518036, Guangdong, Peoples R China
基金
中国国家自然科学基金;
关键词
Cutaneous squamous cell carcinoma; Cutaneous melanoma; m6A modification; m6A-related drugs; Target Therapy; SQUAMOUS-CELL CARCINOMA; MECLOFENAMIC ACID; DEMETHYLASE FTO; N-6-METHYLADENOSINE M(6)A; CRYSTAL-STRUCTURES; IMPROVED SURVIVAL; BINDING-PROTEIN; MEK INHIBITION; SELF-RENEWAL; RISK-FACTORS;
D O I
10.1016/j.gendis.2022.03.006
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
N6-methyladenosine (m6A) is the most abundant internal modification on RNA. It is a dynamical and reversible process, which is regulated by m6A methyltransferase and m6A demethylase. The m6A modified RNA can be specifically recognized by the m6A reader, leading to RNA splicing, maturation, degradation or translation. The abnormality of m6A RNA modification is closely related to a variety of biological processes, especially the occurrence and development of tumors. Recent studies have shown that m6A RNA modification is involved in the pathogenesis of skin cancers. However, the precise molecular mechanisms of m6A-mediated cutaneous tumorigenesis have not been fully elucidated. Therefore, this review will summarize the biological characteristics of m6A modification, its regulatory role and mechanism in skin cancers, and the recent research progress of m6A-related molecular drugs, aiming to provide new ideas for clinical diagnosis and targeted therapy of cutaneous cancers.& COPY; 2022 The Authors. Publishing services by Elsevier B.V. on behalf of KeAi Communications Co., Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons. org/licenses/by-nc-nd/4.0/).
引用
收藏
页码:2320 / 2330
页数:11
相关论文
共 124 条
  • [1] Histone Modifications and Cancer
    Audia, James E.
    Campbell, Robert M.
    [J]. COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY, 2016, 8 (04):
  • [2] LNCAROD is stabilized by m6A methylation and promotes cancer progression via forming a ternary complex with HSPA1A and YBX1 in head and neck squamous cell carcinoma
    Ban, Yuanyuan
    Tan, Pingqing
    Cai, Jing
    Li, Junjun
    Hu, Meng
    Zhou, Ying
    Mei, Yan
    Tan, Yixin
    Li, Xiaoling
    Zeng, Zhaoyang
    Xiong, Wei
    Li, Guiyuan
    Li, Xiayu
    Yi, Mei
    Xiang, Bo
    [J]. MOLECULAR ONCOLOGY, 2020, 14 (06) : 1282 - 1296
  • [3] WTAP is a novel oncogenic protein in acute myeloid leukemia
    Bansal, H.
    Yihua, Q.
    Iyer, S. P.
    Ganapathy, S.
    Proia, D.
    Penalva, L. O.
    Uren, P. J.
    Suresh, U.
    Carew, J. S.
    Karnad, A. B.
    Weitman, S.
    Tomlinson, G. E.
    Rao, M. K.
    Kornblau, S. M.
    Bansal, S.
    [J]. LEUKEMIA, 2014, 28 (05) : 1171 - 1174
  • [4] Promoter-bound METTL3 maintains myeloid leukaemia by m6A-dependent translation control
    Barbieri, Isaia
    Tzelepis, Konstantinos
    Pandolfini, Luca
    Shi, Junwei
    Millan-Zambrano, Gonzalo
    Robson, Samuel C.
    Aspris, Demetrios
    Migliori, Valentina
    Bannister, Andrew J.
    Han, Namshik
    De Braekeleer, Etienne
    Ponstingl, Hannes
    Hendrick, Alan
    Vakoc, Christopher R.
    Vassiliou, George S.
    Kouzarides, Tony
    [J]. NATURE, 2017, 552 (7683) : 126 - +
  • [5] Analysis of risk factor's determining prognosis of cutaneous squamous-cell carcinoma:: a prospective study
    Brantsch, Kay D.
    Meisner, Christoph
    Schoenfisch, Birgitt
    Trilling, Birgit
    Wehner-Caroli, Joerg
    Roecken, Martin
    Breuninger, Helmut
    [J]. LANCET ONCOLOGY, 2008, 9 (08) : 713 - 720
  • [6] The incidence of metastasis from cutaneous squamous cell carcinoma and the impact of its risk factors
    Brougham, Nicholas D. L. S.
    Dennett, Elizabeth R.
    Cameron, Rujuta
    Tan, Swee T.
    [J]. JOURNAL OF SURGICAL ONCOLOGY, 2012, 106 (07) : 811 - 815
  • [7] Organic anion transporters and PI3K-AKT-mTOR pathway mediate the synergistic anticancer effect of pemetrexed and rhein
    Bu, Tianci
    Wang, Changyuan
    Jin, Huan
    Meng, Qiang
    Huo, Xiaokui
    Sun, Huijun
    Sun, Pengyuan
    Wu, Jingjing
    Ma, Xiaodong
    Liu, Zhihao
    Liu, Kexin
    [J]. JOURNAL OF CELLULAR PHYSIOLOGY, 2020, 235 (04) : 3309 - 3319
  • [8] Nivolumab Plus Ipilimumab in Patients With Advanced Melanoma: Updated Survival, Response, and Safety Data in a Phase I Dose-Escalation Study
    Callahan, Margaret K.
    Kluger, Harriet
    Postow, Michael A.
    Segal, Neil H.
    Lesokhin, Alexander
    Atkins, Michael B.
    Kirkwood, John M.
    Krishnan, Suba
    Bhore, Rafia
    Horak, Christine
    Wolchok, Jedd D.
    Sznol, Mario
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04) : 391 - +
  • [9] Dynamic effects of Fto in regulating the proliferation and differentiation of adult neural stem cells of mice
    Cao, Yuhang
    Zhuang, Yingliang
    Chen, Junchen
    Xu, Weize
    Shou, Yikai
    Huang, Xiaoli
    Shu, Qiang
    Li, Xuekun
    [J]. HUMAN MOLECULAR GENETICS, 2020, 29 (05) : 727 - 735
  • [10] Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
    Chapman, Paul B.
    Hauschild, Axel
    Robert, Caroline
    Haanen, John B.
    Ascierto, Paolo
    Larkin, James
    Dummer, Reinhard
    Garbe, Claus
    Testori, Alessandro
    Maio, Michele
    Hogg, David
    Lorigan, Paul
    Lebbe, Celeste
    Jouary, Thomas
    Schadendorf, Dirk
    Ribas, Antoni
    O'Day, Steven J.
    Sosman, Jeffrey A.
    Kirkwood, John M.
    Eggermont, Alexander M. M.
    Dreno, Brigitte
    Nolop, Keith
    Li, Jiang
    Nelson, Betty
    Hou, Jeannie
    Lee, Richard J.
    Flaherty, Keith T.
    McArthur, Grant A.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (26) : 2507 - 2516